

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Gui-Dong Zhu	10/07/2008
RECEIVING PARTY DATA	
Name:	Abbott Laboratories
Street Address:	100 Abbott Park Road
Internal Address:	D-377, AP6A/1
City:	Abbott Park
State/Country:	ILLINOIS
Postal Code:	60064-6008
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12248988
CORRESPONDENCE DATA	
Fax Number:	(847)938-2623
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	8479376364
Email:	sherell.brownlee-davis@abbott.com
Correspondent Name:	Paul D. Yasger
Address Line 1:	100 Abbott Park Road
Address Line 2:	D-377, AP6A/1
Address Line 4:	Abbott Park, ILLINOIS 60064-6008
ATTORNEY DOCKET NUMBER:	9108USO1
NAME OF SUBMITTER:	Rachel A. Polster-sbd
Total Attachments: 2 source=9108USO1AssignmentEXE#page1.tif source=9108USO1AssignmentEXE#page2.tif	

CH 12248988 \$40.00

PATENT

500672575

REEL: 021664 FRAME: 0957

ASSIGNMENT

WHEREAS, Gui-Dong Zhu, 1395 Almanden Ln., Gurnee, IL 60031, hereinafter called the "Assignors", have made the invention described in the United States patent application entitled 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 2 that has received a U.S. Patent Application Serial Number 12/248,988 and was filed on October 10, 2008;

WHEREAS, Abbott Laboratories, a corporation organized and existing under the laws of Illinois, having a place of business at Abbott Park, Illinois 60064, hereinafter called the "Assignee", desires to acquire the entire right, title and interest in and to the invention and to the patent application identified above, and all patents, foreign and domestic, which may be obtained for said invention, as set forth below;

NOW, THEREFORE, in exchange for valuable and legally sufficient consideration, the Assignors have sold, assigned and transferred, and by these presents do sell, assign and transfer to the Assignee, the entire right, title and interest for the United States and elsewhere in and to the invention and the patent application identified above, and any patents that may issue for said invention in the United States and elsewhere; together with the entire right, title and interest in and to said invention and all patent applications, patents, utility models and designs therefore in all countries foreign to the United States, including the full right to claim for any such application all benefits and priority rights under any applicable convention; together with the entire right, title and interest in and to all continuations, divisions, renewals and extensions of any of the patent applications, patents, utility models and designs defined above; to have and to hold for sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents.

The Assignors hereby covenant and agree, for both the Assignors and the Assignors' legal representative, that Assignors have the full right to convey the interest assigned by this Assignment; and that the Assignors will assist the Assignee in the prosecution of the patent applications identified above, in the making and prosecution of any other applications that the Assignee may elect to make covering the invention identified above, in vesting in the Assignee like exclusive title in and to all such other patent applications and patents, in the prosecution of any interference which may arise involving said invention, or any such patent application or patent, and in assisting Assignee in enforcement of any rights arising out of this Assignment; and that the Assignors will execute and deliver to the Assignee any and all additional papers which may be requested by the Assignee to carry out the terms of this Agreement.

The Commissioner of Patents and Trademarks is hereby authorized and requested to issue patents to the Assignee in accordance with the terms of this Assignment.

IN TESTIMONY WHEREOF, the Assignors have executed this agreement.

DATED: 10/7/2008


Gui-Dong Zhu